# A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following Injury

> **NCT07107932** · — · RECRUITING · sponsor: **Zhuhai Trinomab Pharmaceutical Co., Ltd.** · enrollment: 10000 (estimated)

## Conditions studied

- Tetanus

## Interventions

- **DRUG:** Siltartoxatug Injection (Brand name: Sintetol®)

## Key facts

- **NCT ID:** NCT07107932
- **Lead sponsor:** Zhuhai Trinomab Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-31
- **Primary completion:** 2029-03-30
- **Final completion:** 2029-03-30
- **Target enrollment:** 10000 (ESTIMATED)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07107932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07107932, "A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following Injury". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07107932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*